CS Group has appointed Shah Teelani & Associates, a Dubai-based audit firm registered with the Public Company Accounting Oversight Board, to consolidate and audit all 2025 financial statements for the company and its international subsidiaries. The engagement covers CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH, reflecting the Group's commitment to strengthening financial governance and regulatory compliance as it expands across the United States, GCC region, and Europe. Management stated that appointing a PCAOB-registered audit firm represents a significant step in aligning the Group's financial reporting structure with U.S. public company standards while integrating its growing international companies under a unified reporting framework.
The consolidated audit is expected to support enhanced financial clarity, streamlined reporting processes, and strengthened investor confidence. The 2025 financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion. Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group's evolution as a publicly traded company, said Mohammad Essayed, Group Chief Financial Officer. As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy.
The Group continues to focus on expanding manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap. CS Diagnostics Corp. is a medical technology company advancing a dual-focus platform across infection control and oncology, targeting high-priority global healthcare markets. The company's portfolio includes MEDUSA, a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations, and CS Protect-Hydrogel, a tissue spacer designed to protect healthy organs during prostate cancer radiotherapy. For further information, please visit https://group-csd.com/. The announcement contains forward-looking statements relating to expected future events and results that are subject to certain risks and uncertainties, including general economic conditions, regulatory processes, technical issues, and the ability to execute future plans.
